Shionogi & Co Ltd was founded precisely on 17^th March, 1878 with its headquarters located at Osaka, Japan. The company was however incorporated only during 1919. The group is led by the President Motozo Shiono.  The company is considered as the premier research focused Japanese pharmaceutical producer. Manufacturing and marketing of the pharmaceutical products has been the prime activities of Shionogi group of companies. The functions of Shionogi & Co Ltd are managed through different divisions like Pharmaceuticals, Capsules and other. 

 

The pharmaceutical division takes care of producing and commercializing medications like antibiotics, OTC products, diagnostic & clinical testing products, animal health care products, agrochemicals and industrial chemicals, while the capsule division manages health foods and drugs and the other division caters the herbal animal medications, services related to real estates and distribution network.

 

Since the health insurance sector in Japan is de-controlling, the company now has looked forward for licensing MOUs with reputed companies like AstraZeneca and GSK GlaxoSmithKline for developing products even faster. The company has sold out its capsule making facilities following price restrictions enforced by the local government as well as more and more foreign competitions in this sector. The company has founded a drug developing ancillary facility in the United States in order to remain in the race.

 

The product range of Shionogi includes: the anti-hypertensive Landel, the calcium agonist, the ACE inhibitor Longes, the hypercholesterolemia Crestor, the oral antibiotics Flomox, the injectable antibiotics Flumarin and Vancomycin, the carbapenem antibiotics Finibax, the latest quinolone antibiotics Avelox, the anti-allergic Claritin and RediTabs, OxyContin, MS Contin, Oxycodone, Imunace and Aqupla.